Table 2.
Comparison of clinical features of older patients with Parkinson's disease in different drug dose groups.
| 125 mg Levodopa/benserazide (n = 28) | 250 mg Levodopa/benserazide (n = 31) | 375 mg Levodopa/benserazide (n = 24) | Χ2 | P | 125 mg Levodopa/benserazide (n = 28) | 250 mg Levodopa/benserazide (n = 31) | 375 mg Levodopa/benserazide (n = 24) | Χ2 | P | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | 1.077 | 0.584 | Anti-PD drugs | ||||||||
| Male (n, %) | 18 (64.3) | 17 (54.8) | 14 (58.3) | Levodopa (n, %) | 22 (78.6) | 28 (90.3) | 24 (100) | 8.814 | 0.012 | ||
| Female (n, %) | 10 (35.7) | 14 (45.2) | 10 (41.7) | Pramipexole (n, %) | 4 (14.3) | 8 (25.8) | 8 (33.3) | 2.643 | 0.267 | ||
| Piribedil (n, %) | 1 (3.6) | 3 (9.7) | 4 (16.7) | 2.545 | 0.280 | ||||||
| RBD (n, %) | 11 (39.3) | 13 (41.9) | 10 (41.7) | 0.058 | 0.972 | Amantadine (n, %) | 1 (3.5) | 1 (3.2) | 5 (20.8) | 10.653 | 0.005 |
| History of hypertension (n, %) | 12 (42.9) | 16 (51.6) | 13 (54.6) | 2.474 | 0.290 | MAO-B inhibitors (n, %) | 2 (7.1) | 3 (9.7) | 4 (16.7) | 1.027 | 0.598 |
| Antihypertensive drugs (n, %) | 12 (42.9) | 14 (45.2) | 11 (45.8) | 0.162 | 0.922 | COMT inhibitors (n, %) | 1 (3.5) | 3 (9.7) | 3 (12.5) | 0.859 | 0.651 |
| PIGD-dominant (n, %) | 12 (42.9) | 15 (48.4) | 10 (41.7) | 1.771 | 0.413 | Cognitive impairment (n, %) | 8 (28.6) | 11 (35.5) | 10 (41.7) | 2.002 | 0.368 |
| History of Stroke (n, %) | 6 (21.4) | 7 (22.6) | 4 (16.7) | 0.555 | 0.758 | Depression (n, %) | 8 (28.6) | 10 (32.3) | 6 (25) | 1.667 | 0.434 |
| Hyposmia (n, %) | 9 (32.1) | 11 (35.5) | 8 (33.3) | 0.276 | 0.118 | Excessive sweating (n, %) | 5 (17.9) | 6 (19.3) | 3 (12.5) | 0.496 | 0.780 |
| Constipation (n, %) | 18 (64.3) | 19 (61.3) | 16 (66.7) | 0.526 | 0.769 | Salivation (n, %) | 6 (21.4) | 9 (29.0) | 6 (25) | 3.548 | 0.170 |
| Pollakiuria (n, %) | 20 (71.4) | 21 (67.7) | 16 (66.7) | 0.296 | 0.813 | “Off state” OH | 5 (17.9) | 8 (23.5) | 6 (25) | 2.991 | 0.224 |
| Uracratia (n, %) | 9 (32.1) | 10 (32.3) | 9 (37.5) | 0.262 | 0.877 | Best “on state” OH | 6 (21.4) | 10 (32.3) | 9 (32.1) | 2.543 | 0.280 |
Data were represented as numbers (frequencies) and compared using Chi-square test. P-values with statistical significance (<0.05) are in bold.
RBD, rapid eye movement (REM) sleep behavior disorder; PIGD, postural instability/gait difficulty; MAO-B, monoamine oxidase B; COMT, catechol-O-methyltransferase; OH, orthostatic hypotension; “off-state,” defined as the period when all anti-PD drugs were withdrawn for at least 12 h; best “on-state,” defined as the peak of anti-PD drug benefit in the morning.